<DOC>
	<DOCNO>NCT00806585</DOCNO>
	<brief_summary>The study ass efficacy tolerability MK0736 patient Type 2 Diabetes Mellitus Hypertension ongoing therapy Angiotensin-Converting Enzyme Angiotensin Receptor Blocker . After 3 5 week pre-randomization phase , patient randomize either MK0736 ( 3 dos ) , placebo , hydrochlorothiazide ( HCTZ ) . The study also include 3 week , posttreatment follow-up period .</brief_summary>
	<brief_title>Dose-ranging Study Evaluate Effectiveness Tolerability MK0736 Patients With Type 2 Diabetes Mellitus ( T2DM ) Hypertension ( 0736-007 )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Must 18 75 year age Type 2 Diabetes Mellitus ( Glycohemoglobin [ A1CHbA1c ] : 7 10 % ) Hypertension : Diastolic blood pressure ( DBP ; 85 99 mm Hg ) systolic blood pressure ( SBP ; 120 159 mm Hg ) LDLC &lt; 140 mg/dL On stable treatment AngiotensinConverting Enzyme Inhibitor ( ACEI ) Angiotensin Receptor Blocker ( ARB ) History Type I Diabetes mellitus ketoacidosis Patients take 3 blood pressure lower medication Have severe chronic heart failure History certain disease condition cardiac arrhythmia , heart attack , stroke , unstable angina , decompensated vascular disease History cancer within last 5 year Human immunodeficiency virus ( HIV ) Positive Have receive treatment investigational drug within past 30 day History alcohol drug abuse within past 3 year Body Mass Index ( BMI ) &gt; = 41 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>